Wealthcare Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Wealthcare Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-175	Closed	-$2K	–	600
2019 Q4	$2K	Buy	+175	New	+$1.56K	﹤0.01%	561
2016 Q4	–	Sell	-134	Closed	-$6K	–	214
2016 Q3	$6K	Hold	134	–	–	﹤0.01%	142
2016 Q2	$7K	Hold	134	–	–	﹤0.01%	135
2016 Q1	$7K	Hold	134	–	–	﹤0.01%	147
2015 Q4	$9K	Hold	134	–	–	﹤0.01%	146
2015 Q3	$8K	Sell	134 -63	-32%	-$4.08K	﹤0.01%	171
2015 Q2	$12K	Sell	197 -86	-30%	-$5.3K	﹤0.01%	190
2015 Q1	$18K	Buy	283 +149	+111%	+$8.66K	﹤0.01%	423
2014 Q4	$8K	Hold	134	–	–	﹤0.01%	141
2014 Q3	$7K	Hold	134	–	–	﹤0.01%	193
2014 Q2	$7K	Buy	+134	New	+$6.85K	﹤0.01%	143

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Wealthcare Capital Management's TEVA Position: Q1 2020 in Review

Wealthcare Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2020, closing a stake of 175 shares — an estimated $2K sold.

Wealthcare Capital Management first reported a position in TEVA in Q2 2014 and held it in 11 quarters. The position peaked at $18K in Q1 2015. 459 funds tracked by Wall St. Rank hold TEVA as of Q1 2020.

Wealthcare Capital Management reported no remaining Teva Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Wealthcare Capital Management sold 175 Teva Pharmaceuticals shares in Q1 2020, an estimated $2K.
Wealthcare Capital Management first reported a position in Teva Pharmaceuticals in Q2 2014 and held it in 11 quarters.
Wealthcare Capital Management's Teva Pharmaceuticals position peaked at $18K in Q1 2015.
459 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2020.

Based on Wealthcare Capital Management's 13F filing for Q1 2020, filed 29 Apr 2020.